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Research in Context 41 
 42 
Evidence before this study 43 
Patients with heart failure with reduced ejection (HFrEF) experience substantially shorter life 44 
expectancies compared with persons in the general population of similar age. Multiple therapies 45 
are now known to individually extend survival in chronic HFrEF. While most patients are 46 
currently treated with renin-angiotensin-system inhibitors (RASi) and β-blockers, three drug 47 
classes (ARNI, MRA, SGLT2i) have additionally been shown to reduce mortality in HFrEF 48 
beyond these previously established core elements. Real-world data have highlighted incomplete 49 
use of these more recent additions to the therapeutic armamentarium. 50 
 51 
Added value of this study 52 
Leveraging data from 3 contemporary randomized clinical trials in chronic HFrEF, we estimate 53 
that comprehensive disease-modifying pharmacologic therapy (ARNI+β-54 
blocker+MRA+SGLT2i) reduces the hazard of cardiovascular death or HF hospitalization by 55 
62% (HR 0.38; 95% CI 0.30-0.47) compared with limited conventional therapy (ACEi/ARB+β-56 
blocker). Depending on the age of therapeutic optimization, treatment with comprehensive 57 
disease-modifying pharmacologic therapy was estimated to afford 1.4 to 6.3 additional years 58 
alive and 2.7 to 8.3 additional years free from cardiovascular death or HF hospitalization 59 
compared with treatment with ACEi/ARB+β-blocker alone. 60 
 61 
Implications of all the available evidence 62 
Compared with limited conventional neurohormonal medical therapies commonly used in 63 
clinical practice, these data support the central role of comprehensive disease-modifying 64 
pharmacologic therapy to halt or delay clinical progression and extend survival in HFrEF. Given 65 
incomplete uptake of well-established and novel therapies, innovative and disruptive 66 
implementation strategies are urgently needed to facilitate use of combination multi-drug 67 
regimens in appropriately selected patients with HFrEF. The survival benefits estimated with 68 
comprehensive disease-modifying pharmacologic therapy may be important in shared 69 
therapeutic decision-making and future health system valuation.  70 
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Summary 71 
 72 
Background 73 
Three drug classes (mineralocorticoid receptor antagonists [MRA], angiotensin receptor-74 
neprilysin inhibitors [ARNI], and sodium glucose cotransporter-2 inhibitors [SGLT2i]) have 75 
been shown to reduce mortality in heart failure with reduced ejection fraction [HFrEF] beyond 76 
angiotensin-converting enzyme inhibitors/angiotensin receptor blockers [ACEi/ARB] and β-77 
blockers. However, each class was studied with variable background therapy and the expected 78 
treatment benefits with their combined use are not known. 79 
 80 
Methods 81 
We estimated treatment effects of comprehensive disease-modifying pharmacologic therapy 82 
(ARNI+β-blocker+MRA+SGLT2i) vs. limited conventional therapy (ACEi/ARB+ β-blocker) in 83 
chronic HFrEF by making indirect comparisons of pivotal trials. Treatment estimates were 84 
derived from EMPHASIS-HF (n=2,737), PARADIGM-HF (n=8,399), and DAPA-HF (n=4,744). 85 
Assuming these relative treatment effects are consistent over time, we then projected potential 86 
incremental long-term survival gains with comprehensive disease-modifying therapy in the 87 
control arm of the EMPHASIS-HF trial (which required use of ACEi/ARB+β-blocker, unless 88 
contraindicated). 89 
 90 
Findings 91 
The imputed aggregate treatment effects of comprehensive disease-modifying therapy vs. 92 
ACEi/ARB+β-blocker on cardiovascular death or HF hospitalization was 62% (HR 0.38; 95% CI 93 
0.30-0.47). Reductions in hazard of cardiovascular death alone, HF hospitalization alone, and all-94 
cause mortality were 50% (HR 0.50; 95% CI 0.37-0.67), 68% (HR 0.32; 95% CI 0.24-0.43), and 95 
47% (HR 0.53; 95% CI 0.40-0.70), respectively. Based on the 16% annualized event rate of 96 
cardiovascular death or HF hospitalization in the control arm of EMPHASIS-HF, the range of 97 
aggregate treatment effects would translate to an estimated absolute risk reduction with 98 
comprehensive disease-modifying therapy of 18-25% over 3 years with a corresponding number-99 
needed-to-treat of 4 to 6. Treatment with comprehensive disease-modifying pharmacologic 100 
therapy was estimated to afford 2.7 additional years (for an 80-year old) to 8.3 (for a 55 year-old) 101 
additional years free from cardiovascular death or HF hospitalization and 1.4 additional years 102 
(for an 80-year old) to 6.3 (for a 55 year-old) additional years alive compared with limited 103 
conventional medical therapy with ACEi/ARB+β-blocker alone. 104 
 105 
Interpretation 106 
Among patients with HFrEF, the anticipated aggregate treatment effects of early comprehensive 107 
disease-modifying pharmacologic therapy are substantial and may extend survival and event-free 108 
survival by up to 6 years and 8 years, respectively. 109 
 110 
Funding 111 
EMPHASIS-HF was funded by Pfizer. PARADIGM-HF was funded by Novartis. DAPA-HF 112 
was funded by AstraZeneca. 113 
  114 
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Introduction 115 
Patients with heart failure with reduced ejection (HFrEF) experience substantially shorter life 116 
expectancies compared with persons in the general population of similar age.1,2 Over the last 3 117 
decades, there have been stepwise advancements in pharmacotherapy for patients with HFrEF. 118 
While most patients are currently treated with renin-angiotensin-system inhibitors (RASi) and β-119 
blockers,3–5 three drug classes have additionally been shown to reduce mortality in HFrEF 120 
beyond these previously established core elements. Trials have demonstrated clinical superiority 121 
of mineralocorticoid receptor antagonists (MRA)6,7 and sodium-glucose cotransporter-2 122 
inhibitors (SGLT2i)8 when each was tested against a placebo control in addition to standard care 123 
inclusive of RASi and β-blockers (as tolerated). In addition, the angiotensin receptor-neprilysin 124 
inhibitor (ARNI), sacubitril/valsartan, has been shown to be superior when directly tested against 125 
an angiotensin-converting enzyme inhibitor (ACEi) in improving clinical outcomes.9 Real-world 126 
data have highlighted incomplete use of these more recent additions to the therapeutic 127 
armamentarium, even among patients deemed clinically eligible without apparent 128 
contraindication or documented intolerance. For instance, despite class I guideline 129 
recommendations, use of MRAs (33.7% to 35.7%) and ARNI (13.6% to 19.8%) in eligible 130 
patients remains suboptimal. Similarly, although it has been over 4 years since clinical trials have 131 
demonstrated benefits of SGLT2i in high-risk patients with type 2 diabetes, only 2% of HFrEF 132 
patients with comorbid diabetes are currently being treated with SGLT2i in clinical practice.3–133 
5,10,11 These gaps in evidence-based medical therapies have been implicated in relatively stagnant 134 
mortality trajectories of patients living with HFrEF.12 135 
 136 
Communication of the estimated treatment benefits of comprehensive disease-modifying 137 
pharmacologic therapy (ARNI, β-blocker, MRA, & SGLT2i) on clinical outcomes, especially if 138 
used over a lifetime, may facilitate decision-making by patients, clinicians, health systems, and 139 
payers. We first estimated anticipated relative treatment effects of comprehensive disease-140 
modifying pharmacologic therapy vs. limited conventional therapy (ACEi/angiotensin receptor 141 
blocker (ARB)+β-blocker) in chronic HFrEF by making indirect comparisons of pivotal 142 
randomized clinical trials.6,8,13 Using validated actuarial methods and assuming consistent 143 
treatment effects over time, we then project absolute survival gains with comprehensive disease-144 
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modifying pharmacologic therapy if applied long-term, when compared with limited 145 
conventional therapies. 146 
 147 
Methods 148 
Relative Treatment Effects of Comprehensive Disease-Modifying Therapy. To estimate the 149 
effect of comprehensive disease-modifying pharmacologic therapy against previously established 150 
conventional therapy (ACEi/ARB+ β-blocker), we leveraged overall trial-level estimates from 151 
pivotal randomized clinical trials demonstrating the efficacy and safety of MRA,6 ARNI,13 & 152 
SGLT2i.8 Using established methods of indirect comparisons (commonly applied to assess 153 
treatment effects if a placebo was selected in an active-controlled trial),14–17 we estimated 154 
combination effects of comprehensive disease-modifying therapy based on the product of 155 
treatment effects derived from each trial (Supplemental Figure 1). The 95% confidence interval 156 
(CI) was derived from square root of the sum of squared standard errors of the logarithmic 157 
hazard ratios (HR) across all 3 comparisons. All trials required background therapy (as tolerated) 158 
with RASi+β-blocker. As the use of MRA and ARNI was variable in these trials, we derived 159 
conservative estimates of the aggregate treatment effects by additionally assessing treatment 160 
effects in key subgroups treated with these therapies at baseline. 161 
 162 
EMPHASIS-HF. From 2006 to 2010, EMPHASIS-HF (Eplerenone in Mild Patients 163 
Hospitalization and Survival Study in Heart Failure)6 randomized 2,737 patients over the age of 164 
55 years with chronic HFrEF (≤30% or ≤35% with prolonged QRS duration) with New York 165 
Heart Association (NYHA) class II symptoms to eplerenone 25-50mg once daily or matching 166 
placebo. All patients were required to be on maximally tolerated ACEi/ARB and a β-blocker at 167 
baseline. Median duration follow-up was 21 months. 168 
 169 
PARADIGM-HF. From 2009 to 2012, PARADIGM-HF (Prospective Comparison of ARNI 170 
with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial)13 171 
enrolled 10,521 patients at least 18 years of age with HFrEF (≤40%; changed to ≤35% by 172 
protocol amendment) and NYHA functional class II-IV. Patients tolerating sequential single-173 
blind run-in phases with target doses of enalapril and sacubitril/valsartan (n=8,399) were 174 
randomized to enalapril 10mg twice daily or sacubitril/valsartan 200mg twice daily. Treatment 175 
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with stable doses of ACEi/ARB+β-blocker for at least 4 weeks was required by trial protocol. 176 
Median follow-up was 27 months. 177 
 178 
DAPA-HF. From 2017 to 2018, DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes 179 
in Heart Failure)8 randomized 4,744 patients who were age ≥18 years with chronic HFrEF 180 
(≤40%) and NYHA class II-IV symptoms to dapagliflozin 10mg once daily or matching placebo. 181 
Patients with and without diabetes mellitus were evaluated. In sensitivity analysis, we evaluated 182 
the effects of SGLT2i when used in a combination regimen by leveraging subgroup data from 183 
patients at baseline who were treated with ARNI (n=508; 11%). Median follow-up was 18 184 
months. 185 
 186 
Clinical Outcomes. The primary endpoint for the current analysis was composite of 187 
cardiovascular death or first HF hospitalization. Additional endpoints of interest included each of 188 
the components of this composite and all-cause mortality. 189 
 190 
Estimating Gains in Event-Free Survival and Overall Survival. We then simulated event-free 191 
survival and overall survival by applying the treatment effects of comprehensive disease-192 
modifying pharmacologic therapy (as estimated above) to the control arm of the EMPHASIS-HF 193 
trial. We used previously validated actuarial (age-based) methods18 to calculate non-parametric 194 
Kaplan-Meier estimates of survival free from a primary endpoint and overall life expectancy at 195 
every year of age among patients in control arm of the EMPHASIS-HF trial.19 This method uses 196 
age (at baseline and at the time of an event or death) as the time horizon rather than time from 197 
randomization. The area under the survival curve (up to a maximum of 90 years) reflected 198 
projected event-free survival and overall survival. Since age-treatment interactions have not been 199 
observed in each of the pivotal trials,20–22 differences in survival curves reflect projected event-200 
free survival and residual survival. For every age between 55 years (entry criteria for 201 
EMPHASIS-HF) and 80 years, we compared survival estimates of patients in the EMPHASIS-202 
HF control arm as observed in the trial and as simulated if treated with comprehensive disease-203 
modifying pharmacologic therapy. To estimate uncertainty around these survival gains, we 204 
additionally simulated survival under comprehensive medical therapy if the upper and lower 205 
bounds of the relative treatment effect were applied to the EMPHASIS-HF control arm. 206 
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Estimates of survival gains were smoothed with a locally weighted scatterplot smoothing 207 
(LOWESS) procedure. 208 
 209 
Comparator Group of ACEi/ARB+β-blocker+MRA. We finally estimated the incremental 210 
effects of comprehensive pharmacological medical therapy (ARNI, β-blocker, MRA, & SGLT2i) 211 
if patients were already treated with ACEi/ARB+β-blocker+MRA. As a reference population, we 212 
used the eplerenone treatment arm of the EMPHASIS-HF trial (in which baseline use of 213 
ACEi/ARB+β-blocker as tolerated was protocol-specified and patients were randomly assigned 214 
to receive the MRA, eplerenone). To estimate the incremental effects of switching to ARNI and 215 
adding SGLT2i, we applied treatment estimates from subgroup data of those who were treated 216 
with an MRA at baseline in PARADIGM-HF (n=4,671; 56%) and DAPA-HF (n=3,370; 71%). 217 
 218 
All participants provided written consent and the study protocol of each pivotal trial was 219 
approved by the institutional review board at each participating site. All analyses were performed 220 
using STATA, version 14.1 (StataCorp, College Station, TX). P-values<0.05 were considered 221 
statistically significant. 222 
 223 
Role of the Funding Source. The trial sponsors had no role in the design, analysis, interpretation, 224 
writing of the manuscript, or decision to submit this post hoc analysis. The first author and the 225 
corresponding author were responsible for the decision to submit the manuscript. 226 
 227 
Results 228 
Relative Treatment Effects of Comprehensive Disease-Modifying Therapy. For the primary 229 
analysis, we analyzed trial-level estimates from EMPHASIS-HF (n=2,737), PARADIGM-HF 230 
(n=8,399), and DAPA-HF (n=4,744); Table 1. The imputed treatment effect of comprehensive 231 
disease-modifying pharmacologic therapy (with ARNI, β-blocker, MRA, & SGLT2i) vs. limited 232 
conventional therapy (with ACEi/ARB+β-blocker) on the primary endpoint of cardiovascular 233 
death or first HF hospitalization was 62% (HR 0.38; 95% CI 0.30-0.47); Figure 1. Reductions in 234 
hazard of cardiovascular death alone, HF hospitalization alone, and all-cause mortality were 50% 235 
(HR 0.50; 95% CI 0.37-0.67), 68% (HR 0.32; 95% CI 0.24-0.43), and 47% (HR 0.53; 95% CI 236 
0.40-0.70), respectively (Supplemental Figure 1). 237 
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 In sensitivity analysis, we substituted DAPA-HF overall treatment estimates with that 238 
derived from the subset of patients at baseline treated with ARNI (n=508; 11%). The estimated 239 
treatment effects of comprehensive disease-modifying pharmacologic therapy on the primary 240 
endpoint was similar: HR 0.39; 95% CI 0.25-0.61. 241 
  242 
Absolute Event-Free and Total Survival Gains with Quadruple Therapy. We estimated 243 
survival in 1,373 patients in the placebo arm of EMPHASIS-HF. At baseline, an ACEi and/or 244 
ARB was used in 93% of patients and a β-blocker in 87%. Mean age was 68.6±7.6 years; 78% 245 
were men and 83% were white. Mean left ventricular ejection fraction (LVEF) was 26.1±4.7% 246 
and 53% had a prior history of HF hospitalization.  247 
 Over median follow-up of 20.5 (9.5-32.5) months, 356 primary endpoints (25.9%; 248 
16.4[14.8-18.2] per 100 patient-years) and 213 deaths (15.5%; 8.9[7.8-10.2] per 100 patient-249 
years) occurred in the control arm of EMPHASIS-HF. Based on the annualized event rate of 250 
cardiovascular death or HF hospitalization in the control arm of EMPHASIS-HF, the range of 251 
aggregate treatment effects would translate to an estimated absolute risk reduction with 252 
comprehensive disease-modifying pharmacologic therapy of 18-25% over 3 years with a 253 
corresponding number-needed-to-treat of 4 to 6 in the prevention of a primary endpoint. With 254 
respect to mortality, absolute risk reductions were estimated to range between 6-13% over 3 255 
years with a number-needed-to-treat of 8 to 16 in the prevention of 1 death. 256 
 At age 55, the estimated survival free from a primary endpoint was 14.7 years with 257 
comprehensive disease-modifying pharmacologic therapy and 6.4 years with ACEi/ARB+β-258 
blocker (difference: 8.3 years; 95% CI 6.2-10.7 years); Figure 2. At age 55, the estimated overall 259 
residual survival was 17.7 years with comprehensive disease-modifying pharmacologic therapy 260 
and 11.4 years with ACEi/ARB+β-blocker (difference: 6.3 years; 95% CI 3.4-9.1 years); Figure 261 
3. Given that baseline life expectancies varied by age, we further estimated absolute survival 262 
gains across a broad range of ages (55 to 80 years); Figure 4. Treatment with comprehensive 263 
disease-modifying pharmacologic therapy was estimated to afford 2.7 additional years (for an 264 
80-year old) to 8.3 (for a 55 year-old) additional years free from a primary endpoint and 1.4 265 
additional years (for an 80-year old) to 6.3 (for a 55 year-old) additional years alive compared 266 
with limited conventional medical therapy with ACEi/ARB+β-blocker alone.  267 
 268 
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Comparator Group of ACEi/ARB+β-blocker+MRA. If ACEi/ARB+β-blocker+MRA was 269 
selected as the comparator, further therapeutic optimization by switching to ARNI & adding 270 
SGLT2i would be expected to reduce the hazard of the primary endpoint by 36% (HR 0.64; 95% 271 
CI 0.52-0.78). Comprehensive disease-modifying therapy would be estimated to yield 1.2 to 4.1 272 
additional years free from the primary endpoint and 0.8 to 3.1 years alive compared with 273 
treatment with ACEi/ARB+β-blocker+MRA. 274 
 275 
Discussion 276 
A central goal of HF therapeutics is to safely prevent or postpone morbidity-free survival. In 277 
HFrEF, multiple therapeutic advances have offered promise in delaying clinical progression and 278 
extending disease-free survival. Combination therapy with ARNI, β-blocker, and MRA 279 
represents the current guideline-recommended therapeutic standard in HFrEF. In light of robust 280 
and favorable clinical trial data, the addition of SGLT2i in a comprehensive regimen is poised to 281 
be adopted in clinical practice guidelines. Comprehensive disease-modifying pharmacologic 282 
therapies (inclusive of 4 pills, but 5 distinct drugs) now target multiple mechanistic pathways 283 
beyond conventional neurohormonal therapies (ACEi/ARB+β-blocker). While these therapies 284 
have been individually investigated in rigorously conducted randomized clinical trials, the 285 
aggregate effects on clinical outcomes of their combined use had not been directly defined.  286 
 287 
Adequately powered trials evaluating the long-term clinical effects of various therapeutic 288 
combinations may be challenging to conduct with traditional approaches. As such, we applied 289 
established methods available to first estimate the relative treatment effects of comprehensive 290 
disease-modifying pharmacologic therapy and then to forecast these benefits on long-term 291 
survival. ACEi/ARB+β-blocker therapy alone has been previously estimated to lower hazards of 292 
death by 43-53% vs. placebo in historical randomized clinical trials.23 When compared with this 293 
previously established treatment regimen widely administered in clinical practice,3–5 we estimate 294 
that optimization with comprehensive disease-modifying pharmacologic therapy would be 295 
expected to further lower cardiovascular death or HF hospitalization by over 60%. Over 3 years, 296 
the estimated absolute risk reduction was 18-25% with a number-needed-to-treat to prevent 1 297 
event of only 4 to 6. With lifetime use, assuming consistent treatment benefits, these exploratory 298 
actuarial analyses suggest potential event-free survival gains of up to 8 years and absolute 299 
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survival gains of up to 6 years. Even among patients who are already treated with ACEi/ARB+β-300 
blocker+MRA therapy (an evidence-based, guideline-supported strategy that remains 301 
underutilized), we estimate substantial survival benefits with further optimization with switching 302 
to an ARNI and adding an SGLT2i. Younger patients with HFrEF, who would be anticipated to 303 
have longer projected survival and treatment duration, stand to benefit the most from survival 304 
gains related to comprehensive disease-modifying pharmacologic therapy. Yet, for all age groups 305 
analyzed meaningful gains in life-years were projected. These summary data serve as a testament 306 
to the tremendous progress in understanding optimal treatment approaches to chronic HFrEF 307 
garnered from clinical trials conducted over the last 3 decades.  308 
 309 
Each pivotal randomized clinical trial of medical therapy for HFrEF was conducted sequentially 310 
during different eras, and as such, we evaluated the best available data (including subgroups fully 311 
treated on background therapies). While these data do suggest substantial benefits with early 312 
combination therapy, these do not inform a specific therapeutic sequence or pathway for 313 
prioritizing initiation. For instance, although EMPHASIS-HF was conducted prior to 314 
PARADIGM-HF, early switching of ACEi/ARB to ARNI may facilitate subsequent integration 315 
of MRA, due to lower attendant risks of hyperkalemia.24 Conversely, blood pressure lowering 316 
with upstream integration of ARNI may preclude subsequent dose titration or initiation of other 317 
disease-modifying therapies. Similarly, while DAPA-HF mostly recently demonstrated the 318 
therapeutic potential of SGLT2i in HFrEF, earlier use of SGLT2i in therapeutic pathways, prior 319 
to ARNI or MRA, may still be safe and effective. The largely non-overlapping posited 320 
mechanisms of benefit, routes of metabolism, and adverse event profiles argue that both ARNI 321 
and SGLT2i should be rapidly integrated into clinical care of HFrEF, irrespective of specific 322 
order of initiation. 323 
 324 
Accumulating data have suggested that clustered or near-simultaneous initiation and rapid 325 
uptitration of guideline-directed medical therapies are feasible and safe, either under the 326 
guidance of structured ambulatory programs or in hospitalized settings.25 Once these therapies 327 
become broadly available and generic, a polypill of comprehensive disease-modifying therapy 328 
may be feasibly implemented to promote effective and equitable therapy at the population 329 
level.26 While these analyses support the aggregate efficacy of combination, comprehensive 330 
11 
 
disease-modifying pharmacologic therapy, these data do not inform other practical aspects that 331 
may influence decision-making around its implementation. Multi-drug regimens increase the 332 
potential for non-adherence, partially related to incremental out-of-pocket expenditures and 333 
therapeutic complexity. These analyses also do not dissect potential safety issues related to 334 
comprehensive therapy. However, data from pivotal clinical trials have added reassurance that 335 
optimizing therapeutic regimens can be done safely with appropriate follow-up and monitoring. 336 
For instance, in PARADIGM-HF, sacubitril/valsartan resulted in less hyperkalemia and renal 337 
insufficiency compared with enalapril when added to background MRA therapy.24 Similarly, 338 
there were low rates of drug discontinuation or serious adverse events with addition of 339 
dapagliflozin to excellent background medical therapy in DAPA-HF, and these risks were 340 
comparable to those observed with placebo.8 However, understanding tolerability and safety of 341 
comprehensive disease-modifying therapy with real-world use is of high priority. Parallel efforts 342 
to advance implementation science are needed to complement clinical trial evidence to promote 343 
optimal use of therapies at target doses among patients with HFrEF. 344 
 345 
Traditional reporting of treatment effects in clinical trials (such as a HR) is often challenging to 346 
communicate to patients and clinicians. Reductions in potential future events may be difficult to 347 
conceptualize given the lack of a reference.27 Given the chronicity of HF and since trials are 348 
typically conducted over a time course shorter than the life expectancy of a patient, projections 349 
of lifetime application of a given therapy beyond the duration of the trial may better frame its 350 
anticipated long-term benefits. We developed and validated actuarial methods using clinical trial 351 
data to estimate residual lifespan.18 Our estimates of average survival are congruent with 352 
previously published age-specific life expectancy in HF. We estimated that a 55-year old in 353 
EMPHASIS-HF would live on average for 11.4 years; a previous population-based cohort study 354 
from Canada similarly estimated average survival of patients with HFrEF aged 50-60 years to be 355 
11.3± 3.3 years.2 Estimation of life expectancy and quantification of potential survival gains with 356 
a given intervention may facilitate medical decision-making. Communication of the substantial 357 
survival gains free from clinical events may encourage initiation and adherence to combination, 358 
comprehensive disease-modifying pharmacologic medical therapy. 359 
 360 
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The analytic methods employed have important assumptions and limitations. First, we assume 361 
that adherence to therapies and treatment benefits observed during short duration trial follow-up 362 
would be expected to persist long-term. However, greater nonadherence, especially considering 363 
use of multiple therapies, may be expected in usual care settings, which would in turn attenuate 364 
these projected survival gains. Furthermore, it is uncertain whether clinical benefits of these 365 
therapies continue to accrue over lifetime exposure. Second, these methods may overestimate the 366 
expected aggregate effects as we assume additive benefits. It is plausible that the composite 367 
benefits of combination regimens may be partially attenuated due to overlapping mechanistic 368 
pathways. To address this, we conducted sensitivity analyses using subgroup data of patients 369 
treated with various background therapies, which yielded consistent findings. Third, the trials 370 
analyzed in this study were conducted over different time frames with variable populations, 371 
clinical risk, and background therapies. However, as we strictly only considered treatment effect 372 
estimates derived from randomized comparisons within trials, these factors were assumed to be 373 
balanced between treatment arms (as a function of randomization). Furthermore, we only 374 
considered relative (rather than absolute) treatment effects as these may be more comparable 375 
across trials. Fourth, our survival estimates may not be generalizable beyond the scope of these 376 
clinical trial populations. In this analysis, we attempted to provide population-level estimates of 377 
anticipated treatment effects. We did not evaluate variation in survival benefits by specific 378 
patient characteristics (such as race) due to small sample sizes which may produce unstable 379 
estimates and as primary trials detected limited treatment heterogeneity across key subgroups. 380 
However, individual patient factors are important to consider as comprehensive disease-381 
modifying therapies are broadly applied. Fifth, we only included pharmacological therapies that 382 
have been shown to definitively improve survival in general cohorts of patients with HFrEF. We 383 
did not consider therapies that predominantly influence non-fatal HF events (such as digoxin and 384 
ivabradine), therapies that reduce mortality in specific subgroups (such as fixed-dose 385 
combination of isosorbide dinitrate plus hydralazine), and non-pharmacological therapies, 386 
including devices. Sixth, DAPA-HF was the first HF outcomes trial of SGLT2i to report; 387 
ongoing parallel investigations (NCT03057977) will further hone the effect estimates of SGLT2i 388 
as a class in HFrEF. Finally, our analyses focused on therapeutic benefits on key cardiovascular 389 
endpoints, including mortality, and did not account for potential adverse events or costs 390 
associated with use of comprehensive therapy. Despite these limitations, given that long-term 391 
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trials of comprehensive disease-modifying pharmacologic therapy are not available, these novel 392 
analyses from pivotal trials provide the best estimates of their potential combined therapeutic 393 
effects.  394 
 395 
Compared with limited conventional neurohormonal medical therapies commonly used in 396 
clinical practice, these data support the central role of comprehensive disease-modifying 397 
pharmacologic therapy to halt or delay clinical progression and extend survival in HFrEF. Given 398 
incomplete uptake of well-established and novel therapies, innovative and disruptive 399 
implementation strategies are urgently needed to facilitate use of combination multi-drug 400 
regimens in appropriately selected patients with HFrEF. The survival benefits estimated with 401 
comprehensive disease-modifying pharmacologic therapy may be important in shared 402 
therapeutic decision-making and future health system valuation. 403 
 404 
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Figure Legends 535 
Figure 1. Estimation of Relative Treatment Effects of Comprehensive Disease-Modifying 536 
Pharmacologic Therapy on Key Cardiovascular Events 537 
This putative analysis estimates the treatment effects of comprehensive disease-modifying 538 
pharmacologic therapy compared with angiotensin-converting enzyme inhibitor 539 
(ACEi)/angiotensin receptor blocker (ARB)+β-blocker by making indirect comparisons of 540 
pivotal trials in heart failure (HF). 541 
 542 
Abbreviations = ARNI = angiotensin receptor neprilysin inhibitor; CI = confidence interval; CV 543 
= cardiovascular; HR = hazard ratio; MRA = mineralocorticoid receptor antagonist; SGLT2i = 544 
sodium-glucose cotransporter-2 inhibitor. 545 
 546 
Figure 2. Event-Free Survival with Comprehensive Disease-Modifying Therapy (ARNI+β-547 
blocker+MRA+SGLT2i) vs. Limited Conventional Therapy (ACEi/ARB+β-blocker) 548 
Age-based Kaplan–Meier estimated curves are displayed for patients at age 55 years (A) and 65 549 
years (B) for survival free from the primary endpoint, cardiovascular death or heart failure 550 
hospitalization. The control arm of the EMPHASIS-HF (Eplerenone in Mild Patients 551 
Hospitalization and Survival Study in Heart Failure) who were required to be on maximally 552 
tolerated ACEi/ARB+β-blocker therapy served as the reference group (red). The comparator was 553 
a simulated group by applying the estimated treatment effects of comprehensive therapy to the 554 
control arm of the EMPHASIS-HF trial (grey). Residual event-free survival was estimated using 555 
the area under the survival curve up to a maximum of 90 years.  556 
 557 
Abbreviations = ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor 558 
blocker; ARNI = angiotensin receptor neprilysin inhibitor; MRA = mineralocorticoid receptor 559 
antagonist; SGLT2i = sodium-glucose cotransporter-2 inhibitor. 560 
 561 
Figure 3. Long-Term Survival with Comprehensive Disease-Modifying Therapy (ARNI+β-562 
blocker+MRA+SGLT2i) vs. Limited Conventional Therapy (ACEi/ARB+β-blocker) 563 
19 
 
Age-based Kaplan–Meier estimated curves are displayed for patients at age 55 years (A) and 65 564 
years (B) for survival. Residual lifespan was estimated using the area under the survival curve up 565 
to a maximum of 90 years. Methods and abbreviations as per Figure 2. 566 
 567 
Figure 4. Treatment Benefits on Overall Survival and Event-Free Survival with 568 
Comprehensive Disease-Modifying Therapy (ARNI+β-blocker+MRA+SGLT2i) vs. Limited 569 
Conventional Therapy (ACEi/ARB+β-blocker) 570 
Estimated mean event-free survival times (A) and overall survival times (B) in the EMPHASIS-571 
HF control arm and the simulated comprehensive therapy group for every age between 55 and 80 572 
years. Treatment differences and 95% confidence intervals (CI) are estimated for mean event-573 
free survival (C) and overall survival (D) after application of a locally weighted scatterplot 574 
smoothing procedure. The dashed lines represent survival gains if the upper and lower bounds of 575 
the relative treatment effect are applied as the simulated comprehensive therapy group. 576 
Abbreviations as per Figure 1.  577 
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Table 1. Key Baseline Characteristics & Background Medical Therapy 578 
 579 
  EMPHASIS-HF 
(n=2,737) 
PARADIGM-HF 
(n=8,399) 
DAPA-HF  
(n=4,744) 
Comparison 
Eplerenone vs.  
Placebo 
Sacubitril/Valsartan 
vs. Enalapril 
Dapagliflozin vs. 
Placebo 
Enrollment Period 2006-2010 2009-2012 2017-2018 
Median Follow-up (months) 21 27 18 
Age (years) 69 ± 8 64 ± 11 66 ± 11 
Women 610 (22%) 1832 (22%) 1109 (23%) 
Systolic blood pressure (mmHg), mean±SD 124±17 121 ± 15 122 ± 16 
Heart rate (bpm), mean±SD 72±13 72 ± 12 72 ± 12 
Left ventricular ejection fraction (%), 
mean±SD 
26 ± 5 30 ± 6 31 ± 7 
New York Heart Association Class    
1 0 (0%) 389 (5%) 0 (0%) 
2 2737 (100%) 5919 (71%) 3203 (68%) 
3 0 (0%) 2018 (24%) 1498 (32%) 
4 0 (0%) 60 (1%) 43 (1%) 
Atrial fibrillation 844 (31%) 3091 (37%) 1818 (38%) 
Diabetes mellitus 859 (31%) 2907 (35%) 1983 (42%) 
Prior hospitalization for HF 1440 (53%) 5274 (63%) 2251 (47%) 
Diuretics 2326 (85%) 6738 (80%) 4433 (93%) 
ACEi/ARB/ARNI* 2557 (93%) 8379 (100%) 4442 (94%) 
β-blocker 2374 (87%) 7811 (93%) 4558 (96%) 
MRA  -- 4671 (56%) 3370 (71%) 
* DAPA-HF is the only trial that enrolled patients on background ARNI (n=508) 580 
 581 
Abbreviations: ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor-582 
neprilysin inhibitor; HF = heart failure; MRA = mineralocorticoid receptor antagonist; SD = standard deviation 583 
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Figure 1. 584 
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